Personalis

Personalis P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Personalis (PSNL) as of Oct 28, 2026 is -9.73. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -16.15 — a change of -39.76% (higher).

P/CF

-9.73

YoY

-39.76%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Personalis is 2025 -9.73 . P/CF (Price-to-Cash-Flow Ratio) of Personalis was 2024 -16.15 . It decreases by -39.76% higher compared to the previous year.

The Personalis P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
130.85 USD
Jan 1, 2019
-40.35 USD
Jan 1, 2020
-17.09 USD
Jan 1, 2021
-10.29 USD
Jan 1, 2022
-10.38 USD
Jan 1, 2023
-12.96 USD
Jan 1, 2024
-16.15 USD
Jan 1, 2025
-9.73 USD
The Personalis P/CF history
YEARP/CFYoY
-9.73-39.76%
-16.15+24.60%
-12.96+24.84%
-10.38+0.85%
-10.29-39.78%
-17.09-57.64%
-40.35-130.84%
130.85-94.80%
2,514.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

P/CF (Price-to-Cash-Flow Ratio) of Personalis is -9.73 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Personalis changed from -16.15 to -9.73, representing a -39.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Personalis since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Personalis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Personalis

All Key Metrics — Personalis